Coptisine suppresses tumor growth and progression by down-regulating MFG-E8 in colorectal cancer. 2018

Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
The First Clinical College, Nanjing University of Chinese Medicine Nanjing 210023 P. R. China.

Treating colorectal cancer (CRC) continues to be a clinical challenge. Coptisine, an alkaloid derived from Coptis chinensis Franch. shows toxic effects on CRC cells, but its underlying mechanism remains elusive. MFG-E8 is involved in tumor growth and progression. Herein, we evaluated the effects of coptisine on MFG-E8 in CRC, and explored the mechanism. The expression of MFG-E8 in CRC and adjacent normal colon tissue samples from patients was detected. The effects of coptisine on CRC cells HCT116 in vitro were evaluated by CCK-8, adhesion and transwell assays. A xenograft tumor model was used to assess the effects of coptisine in vivo. The morphology of CRC tissue was observed by HE staining. Cell signaling was tested using western blotting and immunohistochemical assay. The expression of MFG-E8 in human CRC tissue samples significantly increased compared with that of adjacent normal ones. Coptisine significantly reduced the expressions of MFG-E8 in HCT116 cells and tumor-bearing mice. Moreover, coptisine suppressed the growth, adhesion and metastasis of CRC cells. Coptisine also suppressed the expression of MMP-2 and MMP-9 via the PI3K/AKT signaling pathway. Furthermore, it inhibited epithelial-mesenchymal transition in vivo and in vitro. Coptisine inhibited CRC growth and progression by down-regulating MFG-E8, and is a potential candidate for treatment.

UI MeSH Term Description Entries

Related Publications

Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
June 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
September 2017, Scientific reports,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
April 2017, Archives of medical research,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
November 2000, Cancer research,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
October 2019, Journal of dermatological science,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
January 2021, Journal of neuroinflammation,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
February 2014, Cancer epidemiology,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
January 2012, PloS one,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
September 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Qianyu Cao, and Shengwei Hong, and Yuanyuan Li, and Heng Chen, and Yining Shen, and Kang Shao, and Mengjie Lu, and Hui Dai, and Shitang Ma, and Guoliang Dai
January 2023, Cell death & disease,
Copied contents to your clipboard!